SCLX · Scilex Holding Co
4 customers — 95% of revenue (three months ended March 31, 2026)
“These customers accounted for 95% of the Company’s revenue for the three months ended March 31, 2026, with each individually ranging from 13% to 28%.”
Key customers — 86% of receivables (March 31, 2026)
“As of each of March 31, 2026 and 2025, these customers represented 86% and 89% of the Company’s outstanding accounts receivable, individually ranging between 6% and 31%, and 18% and 37% for respective periods.”
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCLX
this stock
Scilex Holding Co
|
$55.70M | -13.6% | -46.5% | — | 2.5% |
|
LLY
ELI LILLY & Co
|
$1.15T | +12.8% | +44.7% | 43.4 | 1.1% |
|
JNJ
Johnson & Johnson
|
$639.90B | +29.0% | +6.0% | 30.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$465.02B | +16.2% | +8.6% | 129.7 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$321.97B | +25.7% | +1.4% | 36.7 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCLX | -6.7% | -15.9% | +20.4% | -15.9% | -13.6% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -4.3% | -13.6% | +14.1% | -13.6% | -20.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.